Remdesivir, the first coronavirus drug, gets a price tag

Remdesivir, the first coronavirus drug, gets a price tag
Remdesivir, the first drug shown to be effective against the coronavirus , will be distributed under an unusual agreement with the federal government that establishes non-negotiable prices and prioritizes American patients, health officials announced Monday.

The arrangement may serve as a template for distribution of new treatments and vaccines as the pandemic swells, said Ernst Berndt, a retired health economist at the Massachusetts Institute of Technology Sloan School of Management.

Remdesivir will be sold for $520 (U.S.) per vial, or $3,120 per treatment course, to hospitals for treatment of patients with private insurance, according to the Department of Health and Human Services and Gilead Sciences, the drug’s manufacturer.

The drug will be sold only in the United States through September, meaning U.S. patients will receive almost the entirety of Gilead’s output, more than 500,000 treatment courses.

HHS and state health departments have been allocating the drug to hospitals nationwide based on need. After September, they will no longer have a role in determining where the drug is sent.

“This is a U.S.-first policy,” said Rena Conti, a health care economist at Boston University. “Access is guaranteed to the U.S., but worldwide demand could potentially outstrip supplies.”

“I am unaware of any other policy except perhaps in bioterrorism drugs where there might be country-specific supplies,” she added.

The drug’s eventual cost has always been uncertain. “There is no playbook for how to price a new medicine in a pandemic,” Daniel O’Day, chief executive of Gilead, said in a statement.

The new pricing is not exorbitant, many experts said. Other promising drugs now in late-stage testing are already on the market for other purposes, Conti noted, and cost several times more than remdesivir.
Read more on Toronto Star
News Topics :
Similar Articles :
Reuters Gilead Sciences Inc GILD.O faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected...
WASHINGTON Reuters Gilead Science Inc’s GILD.O antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID 19 on Friday, clearing the...
The promise and limitations of remdesivir, the first drug to prove capable of helping fight Covid 19 , have kicked off efforts to see if it can work better in combination...
Gilead Sciences, the pharmaceutical company behind the COVID 19 treatment remdesivir , just announced what it will charge for the antiviral drug. Patients with health insurance from a private company can...
Top Stories
In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Gilead Sciences...